Rp.31 The Effects Of Rosiglitazone In Postprandial Inflammatory Response In Type 2 Diabetes I.

Author(s): 
Lentzas1, L. Salvanos1, E. Katsanaki1, A. Kamaratos1, G. Belos2
1 Tzanio, Piraeus, Greece
2 Health centre Of Koropi, Athens, Greece
Text: 
Aim.
We postulated that in type 2 diabetes, the postprandial phase is a pro-inflammatory state that can be modulated by PPAR-agonists. For this purpose, we determined the effects of rosiglitazone (8 mg/d) on postprandial leukocyte counts and pro-inflammatory cytokines (EL-6 and EL-8) in patients with type 2 diabetes.
Methods and Results.
A randomized, 8-week, cross-over, placebo-controlled, double-blind clinical trial was performed in 19 patients with type 2 diabetes. Standardized 6-h oral fat-loading tests were performed after each treatment period. During placebo treatment, blood leukocytes increased to a maximum 6-h postprandial, due to significant increases in neutrophils and lymphocytes. Concomitant postprandial increases were observed for IL-6 and EL-8, the major chemokines responsible for leukocyte recruitment. Rosiglitazone reduced the incremental area under the curves (dAUCs) for IL-6 (-63%, p Conclusions.
Rosiglitazone attenuated the postprandial increases of neutrophils, EL-6 and EL-8 in patients with type 2 diabetes. Since inflammation is a major force driving atherosclerosis, and man lives in a postprandial period most part of the day, a reduced inflammatory response after a meal may delay progression of atherosclerosis.
Literature: 
RP.31 THE EFFECTS OF ROSIGLITAZONE IN POSTPRANDIAL INFLAMMATORY RESPONSE IN TYPE 2 DIABETES I.